• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
COVID-19 and Women’s Health

SARS-CoV-2 Vaccines Do Not Cause Female Sterility

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Some people on social media have claimed that there is an alleged similarity between syncytin-1 and the SARS-CoV-2 spike protein which, through immune cross-reactivity, could lead to female sterility
  • Morris (F&S Reports, 2021) used frozen embryo transfer to compare the implantation rates between SARS-CoV-2 seropositive vs seronegative women

METHODS:

  • Cohort study
  • Participants
    • Women undergoing frozen embryo transfer (FET)
  • Exposures
    • Seropositive due to vaccination (Pfizer or Moderna)
    • Seropositive due to natural infection
    • Seronegative
  • Study design
    • Levels of SARS-CoV-2 IgG were determined from serum samples obtained prior to FET
    • All transfers used a single expanded blastocyst in a hormone-prepared uterus
    • Transfer was performed under transabdominal ultrasound guidance
  • Primary outcomes
    • Embryo implantation rates
      • Serum hCG level of >5 mIU/mL obtained 8 days after transfer, followed by a rising level two to three days later
    • Sustained implantation rates
      • Presence of ultrasound visualized fetal heart tones at two time points at least one week apart

RESULTS:

  • 148 patients
    • Seropositive: 37.8%
      • Due to vaccination: 64.8%
      • Due to natural infection: 35.2%
    • Baseline characteristics were similar between exposure groups, except for higher mean BMI in the post-infection group than the vaccinated group and the nonreactive group (P = 0.005)
  • There was no difference in embryo implantation rates between the groups (P=0.99)
    • Vaccine seropositive: 80.0%
    • Infection seropositive: 73.7%
    • Seronegative: 73.9%
  • There was also no difference in sustained implantation rates between the groups (P=0.99)
    • Vaccine seropositive: 65.7%
    • Infection seropositive: 47.4%
    • Seronegative: 52.3%

CONCLUSION:

  • SARS-CoV-2 seropositivity, whether from vaccination or infection, does not prevent embryo implantation or early pregnancy development
  • Claims that SARS-CoV-2 spike protein may induce cross-reactivity with syncytin-1 appear unfounded
  • The authors state

Physicians and public health personnel can counsel women of reproductive age that neither previous illness with COVID-19 nor antibodies produced from vaccination to COVID-19 will cause sterility

Learn More – Primary Sources:

SARS-CoV-2 spike protein seropositivity from vaccination or infection does not cause sterility

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 and Women’s Health Posts
Next >

Related ObG Topics:

mRNA COVID-19 Vaccine Safety in Pregnant Women
Vaccines in Pregnant and Lactating Women: Is Immune Response Similar to that of Non-Pregnant Patients?
Latest Data on Transplacental Antibody Transfer Following COVID-19 Vaccination

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site